--AbbVie is close to a deal to acquire Cerevel Therapeutics Holdings for about $8 billion, Reuters reports, citing people familiar with the matter. --AbbVie is in talks to pay around $45 a share for Cerevel, which develops drugs for neurological conditions. --AbbVie and Cerevel didn't immediately respond to requests for comment from Reuters. Full article at https://www.reuters.com/markets/deals/abbvie-nears-roughly-8-billion-drug-developer-cerevel-sources-2023-12-06/Write to Ben Glickman at ben.glickman@wsj.com(END) Dow Jones Newswires12-06-23 1644ET

Source: Wall Street Journal December 06, 2023 21:48 UTC